Hemab Therapeutics (COAG US)\u00a0delivered one of the standout biotech debuts of 2026, combining strong deal dynamics with powerful aftermarket momentum. The company priced 16.75 million shares\u2014upsized again from 15.0 million\u2014at $18.00, the high end of the range, signaling robust institutional demand heading into the offering. That demand translated immediately into price action, with shares opening at $27.00, which ultimately marked the low of the session. From there, the stock traded with consistent strength throughout the day, reaching an intraday high of $36.61 before closing at $34.00\u2014an 88.9% gain from the IPO price.<\/p>\n
The magnitude and consistency of the move point to a tightly allocated deal with limited float. Channel checks confirm that the offering was multiple times oversubscribed, with allocation heavily concentrated among top-tier investors. The top ten accounts reportedly received approximately 75% of the deal, while the top 25 investors controlled roughly 95% of shares. This level of concentration typically creates scarcity in the open market, and that dynamic was clearly reflected in the stock\u2019s steady upward trajectory and lack of meaningful intraday pullbacks.<\/p>\n
This marks another strong outcome for an RA Capital-backed biotech, reinforcing the firm\u2019s track record of supporting high-performing IPOs. The sponsorship base not only helped anchor demand during the bookbuilding process but also appears to have contributed to disciplined selling behavior on day one. With limited stock available and high conviction among core holders, incremental demand in the secondary market drove outsized gains.<\/p>\n
From a relative performance standpoint, Hemab\u2019s debut ranks as the second-best IPO of 2026, trailing only\u00a0VeraDermics (MANE US)\u00a0, which posted a 122% first-day return. That places Hemab firmly in the upper tier of recent biotech offerings and underscores the re-emergence of strong investor appetite for differentiated, later-stage clinical stories.<\/p>\n
Avalyn Pharma (AVLN US)\u00a0delivered a standout IPO debut, pricing 16.7 million shares at $18.00\u2014the high end of its indicated range\u2014after upsizing the deal from 11.8 million shares via a mid-week S-1\/A amendment. Strong institutional demand, supported by a multiple-times oversubscribed order book, enabled the company to both increase deal size and maximize pricing, signaling high conviction from investors ahead of the offering.<\/p>\n
The stock opened at $26.00, representing a 44.4% gain from the IPO price, and notably did not trade below that level throughout the session\u2014an indication of tight allocations and strong early aftermarket support. Shares continued to build momentum intraday, reaching a high of $30.20 before closing at $29.49, capping a highly successful first day with a gain of approximately 63.8% from the offer price. The absence of early selling pressure and steady upward trajectory suggest a well-constructed book dominated by long-only, sector-focused investors rather than short-term participants.<\/p>\n
The 63.9% return at the end of day one ended as fourth best for the 2026 calendar year behind \u00a0VeraDermics (MANE US) (122%), Hemab Therapeutics (COAG) (89%) and SpyGlass Pharma (SGP US)\u00a0(65%).<\/p>\n
Seaport Therapeutics (SPTX US)\u00a0delivered a solid, though somewhat uneven, first day of trading following a heavily anticipated IPO. The company priced 14.2 million shares at $18.00, upsized from the originally marketed 11.8 million shares and at the top end of the indicated range, reflecting strong institutional demand. Shares opened at $21.00, representing a 16.7% premium to the IPO price, and traded as high as $23.00 intraday before losing momentum into the close. The stock ultimately finished the session at $19.84, marking a 10.2% gain on the day.<\/p>\n
While the positive close underscores healthy demand for the deal, the late-day fade suggests a degree of near-term profit taking and a less stable aftermarket than typically seen in the strongest biotech IPO debuts.<\/p>\n
Investor appetite for the offering was robust, with the deal reportedly oversubscribed by more than 10x. Demand was highly concentrated among top-tier accounts, with the 10 largest investors receiving over 65% of the allocation and the top 25 accounts taking approximately 95% of the shares. This level of concentration indicates strong conviction from leading healthcare-focused funds and crossover investors, but may also contribute to increased volatility in early trading as positioning adjusts post-allocation.<\/p>\n
The upsizing of the deal and pricing at the high end further reflect confidence from both the issuer and underwriters in the strength of the order book. However, the trading pattern suggests that a portion of demand may have been driven by short-term participants rather than long-duration holders.<\/p>\n
Silver Bow Mining<\/span><\/span> appeared positioned for a strong IPO, with deal dynamics pointing to multiple-times oversubscription and an eventual upsizing, but the aftermarket told a different story as the stock opened below its issue price. The company priced 5.2 million shares at $11.50, the midpoint of the range, yet shares failed to gain traction, trading as high as $11.23 and as low as $9.73 during the debut session. Allocation was heavily concentrated, with the top 10 investors receiving 60% of the deal and the top 25 accounting for 80%, and management was notably involved in the allocation process; despite these efforts, the stock did not deliver the expected performance, closing both its first and second trading sessions at $10.75.<\/p>\n The Pershing Square USA (PSUS US)\u00a0raised $5 billion total, including $2.8b in a private placement in its closed end fund which was the “minimum amount needed” in order to complete the transaction. The opening trade was $42.00 marking an instant 16.0% loss for investors. Ackman attempted to “soften” the initial blow from the offering by giving one share in its management company (Symbol: PS) for every five shares purchased. The PS shares opened up at $24.00\/share.<\/p>\n From a pure mechanical standpoint, for every 100 shares purchased, investors would $800. The free 20 shares netted investors $420 in this scenario. If investors dumped both stocks at first trade, the loss would be $320 for every 100 shares purchased. With\u00a0The Pershing Square USA (PSUS US)\u00a0closing the day at $40.90 and the PS shares finishing at $24.20, the net loss for every 100 shares held at the end of day one was $426.<\/p>\n Closed-end funds often struggle in the near term, and this transaction proved no exception. Despite evident investor interest, those backing the offering appear to be taking a longer-term view, particularly given confidence in Bill Ackman. With multiple uncertainties leading into the debut, the setup looked muddled in the short run, which ultimately played out. Longer term, however, much of the initial risk has been reduced, potentially giving conviction investors an opportunity to build positions. The PSUS stock traded as high as $44.00 on Friday and closed the week at $42.80 which the PS (management company) stock lifted to a high of $38.27 and closed at $37.99.<\/p>\n For what its worth, investors who held through Friday actually netted a positive outcome of $39.80 for every 100 shares when taking account the “free share” for every five purchased in the offering.<\/p>\n","protected":false},"excerpt":{"rendered":" Hemab Therapeutics (COAG): RA Capital Strikes Again, Hemab Rips Higher on Day One Hemab Therapeutics (COAG US)\u00a0delivered one of the standout biotech debuts of 2026, combining strong deal dynamics with powerful aftermarket momentum. The company priced 16.75 million shares\u2014upsized again from 15.0 million\u2014at $18.00, the high end of the range, signaling robust institutional demand heading[…]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[1536],"tags":[],"class_list":["post-32595","post","type-post","status-publish","format-standard","hentry","category-subscriber-content"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/32595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=32595"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/32595\/revisions"}],"predecessor-version":[{"id":32596,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/32595\/revisions\/32596"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=32595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=32595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=32595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Pershing Square USA (PSUS): Incentive Fails to Lift Ackman’s Fund Debut on Day One<\/h1>\n